Puma Biotechnology | PBYI - Ebitda


Puma Biotechnology reported $729K in EBITDA for its fiscal quarter ending in June of 2024.





Ebitda Change Date
Agios Pharmaceuticals USD -108.66M 11.65M Mar/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Amgen USD 3.86B 1.28B Mar/2026
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Exelixis USD 255.4M 2.89M Jun/2026
Gilead Sciences USD 3.51B 489M Mar/2026
Glaxosmithkline GBP 2.77B 1.98B Mar/2026
Incyte USD 778.57M 410.6M Jun/2026
MacroGenics USD -30.2M 52.15M Mar/2026
Moderna USD -1.26B 468M Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Pfizer USD 6.01B 18M Jun/2026
PTC Therapeutics USD 61.98M 132.97M Mar/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
Takeda JPY 364.46B 214.21B Jun/2026
TG Therapeutics USD 26.9M 1.21M Jun/2026
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026